Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00345527
Status:
WITHDRAWN
Last Update Posted:
2013-02-13
First Post:
2006-06-27
Brief Title:
A Randomized Control Trial Examining Two Treatments for Problem Gambling
Sponsor:
Centre for Addiction and Mental Health
Organization:
Centre for Addiction and Mental Health
Study Overview
Official Title:
A Randomized Control Trial Examining Two Treatments for Problem Gambling
Status:
WITHDRAWN
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study moved to British Columbia
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Despite evidence of high rates of concurrent substance use and anger problems among problem gamblers until recently there have been no empirically evaluated treatments for these co-morbid problems A recent study Korman Collins McMain Skinner 2005 found that an emotion and behaviour regulation treatment EBRT was more effective than a gambling-only treatment-as-usual in engaging clients in treatment and in reducing gambling anger and substance use This study is a replication of Korman et als study and will compare an emotion and behaviour regulation treatment EBRT for problem gambling anger and substance use to a manualized cognitive behavioural treatment CBT for problem gambling
Detailed Description:
80 participants will be randomly assigned to either an emotion and behaviour regulation treatment EBRT or to a cognitive behavioural treatment CBT Randomization will be stratified by the presence of substance dependence disorder Both treatment conditions will consist of 12 one-hour weekly outpatient individual sessions Participants will be assessed at baseline end of treatment and 3-months 6-months and 12-months follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None